Literature DB >> 18625116

What are the long-term cardiovascular effects of treatment with rosiglitazone?

Fiby Nessim, Lisel Loney-Hutchinson, Samy I McFarlane.   

Abstract

Entities:  

Year:  2008        PMID： 18625116     DOI： 10.1007/s11892-008-0034-x

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  6 in total

Review 1.  Thiazolidinediones.

Authors:  Hannele Yki-Järvinen
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

2.  Rosiglitazone and cardiovascular risk.

Authors:  Bruce M Psaty; Curt D Furberg
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

3.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Authors:  Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

4.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Authors:  H C Gerstein; S Yusuf; J Bosch; J Pogue; P Sheridan; N Dinccag; M Hanefeld; B Hoogwerf; M Laakso; V Mohan; J Shaw; B Zinman; R R Holman
Journal:  Lancet       Date:  2006-09-23       Impact factor: 79.321

Review 5.  Nonhypoglycemic effects of thiazolidinediones.

Authors:  A A Parulkar; M L Pendergrass; R Granda-Ayala; T R Lee; V A Fonseca
Journal:  Ann Intern Med       Date:  2001-01-02       Impact factor: 25.391

6.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.